

Bile Duct Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/B187175640F2EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: B187175640F2EN

Abstracts

The 7 major bile duct diseases markets are expected to exhibit a CAGR of 8.21% during 2024-2034.

The bile duct diseases market has been comprehensively analyzed in IMARC's new report titled "Bile Duct Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bile duct diseases encompass a range of conditions affecting the intricate network of tubes that transport bile from the liver to the small intestine. Bile, essential for digestion and waste elimination, flows through these ducts. The symptoms of these ailments can vary widely but often include jaundice, characterized by yellowing of the eyes and skin, resulting from the buildup of bilirubin. Abdominal pain, nausea, vomiting, and pale stools might also arise. The diagnosis of bile duct diseases involves a comprehensive approach. Healthcare providers usually begin with a thorough medical history and physical examination to assess symptoms and potential risk factors. In addition to this, blood workups can help to reveal elevated levels of liver enzymes and bilirubin. Several imaging techniques, such as ultrasound, CT scans, MR, etc., that provide detailed views of the bile ducts and surrounding structures are utilized to aid in the identification of obstructions, strictures, or various other abnormalities.

The increasing incidences of gallstones, which can cause scar tissue formation, leading to blockages, are primarily driving the bile duct diseases market. In addition to this, the inflating utilization of advanced therapeutic medications, including ursodeoxycholic acid, obeticholic acid, and immunosuppressants, to effectively manage symptoms and curtail disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of endoscopic procedures and minimally invasive techniques

aimed at alleviating bile duct obstructions, enhancing drainage, and addressing strictures is further propelling the market growth. These interventions encompass endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC), among others, which collectively contribute to improved patient outcomes. Apart from this, the emerging usage of liver transplantation, since it helps to treat advanced cases by replacing the compromised liver and addressing the underlying disease process in patients, is acting as another significant growth-inducing factor. Additionally, the rising awareness campaigns by healthcare organizations about the risk factors, indications, and treatment options available for these illnesses are also augmenting the market growth. Furthermore, the ongoing research in the fields of molecular biology and genetics aimed at understanding the underlying causes of the ailment at a cellular level to develop novel targeted therapies is expected to drive the bile duct diseases market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the bile duct diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bile duct diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bile duct diseases market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the bile duct diseases market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the bile duct diseases market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bile duct diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the bile duct diseases market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the bile duct diseases market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the bile duct diseases market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of bile duct diseases across the seven major markets?

What is the number of prevalent cases (2018-2034) of bile duct diseases by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of bile duct diseases by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of bile duct diseases by type across the seven major markets?

How many patients are diagnosed (2018-2034) with bile duct diseases across the seven major markets?

What is the size of the bile duct diseases patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of bile duct diseases?

What will be the growth rate of patients across the seven major markets?

Bile Duct Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for bile duct diseases drugs across the seven

major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bile duct diseases market?

What are the key regulatory events related to the bile duct diseases market?

What is the structure of clinical trial landscape by status related to the bile duct diseases market?

What is the structure of clinical trial landscape by phase related to the bile duct diseases market?

What is the structure of clinical trial landscape by route of administration related to the bile duct diseases market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 BILE DUCT DISEASES - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 BILE DUCT DISEASES - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 BILE DUCT DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Epidemiology by Type (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)
 - 7.7.4 Epidemiology by Gender (2018-2034)
 - 7.7.5 Epidemiology by Type (2018-2034)
 - 7.7.6 Diagnosed Cases (2018-2034)
 - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Epidemiology by Type (2018-2034)
 - 7.8.6 Diagnosed Cases (2018-2034)
 - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Epidemiology by Type (2018-2034)
 - 7.9.6 Diagnosed Cases (2018-2034)
 - 7.9.7 Patient Pool/Treated Cases (2018-2034)

8 BILE DUCT DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 BILE DUCT DISEASES - UNMET NEEDS

10 BILE DUCT DISEASES - KEY ENDPOINTS OF TREATMENT

11 BILE DUCT DISEASES - MARKETED PRODUCTS

- 11.1 List of Bile Duct Diseases Marketed Drugs Across the Top 7 Markets

11.1.1 Ocaliva (Obeticholic Acid) - Intercept Pharmaceuticals

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

11.1.2 Urso 250 (Ursodiol) - Allergan

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 BILE DUCT DISEASES - PIPELINE DRUGS

12.1 List of Bile Duct Diseases Pipeline Drugs Across the Top 7 Markets

12.1.1 Elafibranor - Genfit

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 Seladelpar - CymaBay Therapeutics

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

12.1.3 Setanaxib - Calliditas Therapeutics Suisse SA

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

12.1.4 CNP-104 - COUR Pharmaceutical Development Company

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

12.1.5 LJN452 - Novartis Pharmaceutical

12.1.5.1 Drug Overview

12.1.5.2 Mechanism of Action

12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. BILE DUCT DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. BILE DUCT DISEASES – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 BILE DUCT DISEASES - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Bile Duct Diseases - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Bile Duct Diseases - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Bile Duct Diseases - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Bile Duct Diseases - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Bile Duct Diseases - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Bile Duct Diseases - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Bile Duct Diseases - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Bile Duct Diseases - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Bile Duct Diseases - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Bile Duct Diseases - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Bile Duct Diseases - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Bile Duct Diseases - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Bile Duct Diseases - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Bile Duct Diseases - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Bile Duct Diseases - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Bile Duct Diseases - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Bile Duct Diseases - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Bile Duct Diseases - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Bile Duct Diseases - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Bile Duct Diseases - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Bile Duct Diseases - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Bile Duct Diseases - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Bile Duct Diseases - Access and Reimbursement Overview

16 BILE DUCT DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 BILE DUCT DISEASES MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 BILE DUCT DISEASES MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Bile Duct Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/B187175640F2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B187175640F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

